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Abstract
Cancer precursor/progenitor cells may initiate and sustain the growth of tumors, but evidence for
their existence in human disease is indirect, relying on their in vitro properties and animal models.
More directly, specific elimination of these rare cells from cancer patients should produce a delayed
but progressive disappearance of differentiated malignant progeny. Here, we describe selective
eradication of a putative precursor population in a patient with B-cell chronic lymphocytic
leukemia, followed 6 months later by a progressive loss of mature tumor cells without further
treatment. This outcome supports the presence of a rare population of precursor/progenitor cells
in human malignancies, and suggests benefit from their removal.
Findings
Tumors may contain a distinct minority population of
"stem cells", but to date only indirect evidence exists that
such cells initiate or sustain human cancers [1,2]. The
putative stem cell population has been distinguished by a
particular surface phenotype, which may be unique to a
given tumor type, or by certain functional properties, such
as the ability to efflux Hoechst dyes, which produces a dis-
tinct side-population (SP) of cells on fluorescent analysis
[3]. Irrespective of their distinguishing characteristics,
these subpopulations exhibit asymmetric cell division,
enhanced proliferation and greater facility to form tumors
in mice [4-9]. Although suggestive, none of these criteria
are definitive of a cancer stem cell, and analysis may be
confounded by artifacts of the system used for study [9].
Moreover, some tumor cells, such as those from B cell
chronic lymphocytic leukemia (B-CLL) grow poorly in
vitro and in animal models, further hampering identifica-
tion of a true stem cell population. It is not possible to
identify a human tumor stem cell population with abso-
lute rigor, since this would require demonstration that
only the putative stem cell population could induce dis-
ease when administered to human subjects. It is, however,
feasible to attempt to demonstrate the reverse, and show
how selective removal of a putative stem cell population
is followed, after a delay, by the subsequent and progres-
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sive loss of the bulk population which is unable to sustain
itself past the life span of the "committed" tumor cells. We
now describe how administration of a B-CLL tumor cell
vaccine generated a transient immune response that selec-
tively and completely removed a putative precursor popu-
lation, identified by SP analysis, in B-CLL cells from
peripheral blood, but had no initial effect on lymphos-
plenomegaly or total (non-SP) B-CLL cell counts. Contin-
ued follow-up over the following 18 months, however,
revealed a progressive and continuing reduction in the
bulk (non-SP) peripheral blood B-CLL count and in lym-
phosplenomegaly that began 6 months after completion
of immunization and continued progressively over the
next 12 months.
At the time of study entry, P1300 was a 65 old male with
Stage IV B-CLL, diagnosed 2 years previously. He had
received no treatment before vaccination. Pre-vaccination
staging showed multiple enlarged lymph nodes by CT
scan in the neck, axilla, mediastinum abdomen and
inguinal region, splenomegaly (20 × 18 × 8 cm), WBC
(31,000/μL), hemoglobin (12.7 gm/dL), platelets
(84,000/μL), β2 macroglobulin (4.4 mg/mL), reticulocyte
count (1.0%), LDH (211 U/L), diffuse lymphoid infiltrate
consistent with B-CLL on bone marrow biopsy, and dele-
tion of 11q and 13q on FISH. After informed consent, he
was immunized with CD40L and IL-2 gene-modified,
irradiated autologous B-CLL cells on a RAC-NIH, FDA and
IRB approved protocol [10]. Briefly, PBMC (>90% CD5/
CD19/CD20) were harvested from P1300 and co-cultured
on MRC-5 (a human embryonic lung fibroblast cell line;
ATCC) transduced with human CD40L and interleukin-2
(IL-2) as previously described [10]. After confirmation of
transduction by flow cytometry for hCD40L (94%) and
IL-2 secretion (2,412 pg/ml/106 leukemic cells), the gene-
modified tumor vaccine was irradiated (30 Gy) and cryo-
preserved. P1300 subsequently received 6 subcutaneous
injections on weeks 0, 1, 2, 6, 8 and 10.
Prior to vaccination, PBMC from P1300 were labeled with
Hoechst 33342 as previously described [3], and co-stained
with CD5 and CD19 antibodies to discriminate tumor
cells from normal B lymphocytes. Flow cytometry
detected a distinct CD5+CD19+ SP phenotype (Figure 1a).
We excluded the possibility of non-specific staining by
Verapamil inhibition, and confirmed that CD5+CD19+ SP
cells are restricted to leukemic patients by examining the
peripheral blood from healthy donors, where 0/5 con-
tained SP cells (not shown). We next followed the
CD5+CD19+ SP cells in P1300's PBMC during (weeks 3
and 6) and after vaccination (10 weeks to 2.5 years post-
immunization). The distinct SP population present prior
to immunization diminished and then disappeared dur-
ing immunization (Figure 1b) even though no equivalent
change was initially observed in total B-CLL counts (Fig-
ure 2a). During vaccination, the T cell immune response
to autologous B-CLL tumor cells (as measured by the fre-
quency of IFN-γ and IL-5 ELIspots) was markedly
increased (Figure 2b). However, this immune response
diminished after immunization, returning to baseline 6
weeks after the last vaccination. The SP cells, however, did
not return. Hence, a detectable B-CLL-specific T cell
immune response was associated with the observed
decrease in CD5+CD19+ SP cells in the peripheral blood of
the patient. The loss of SP cells following immunization
was selective, since there was no overall disease response
to the vaccine during initial follow-up (Figure 2a). After 6
months, however, this patient began to show a progres-
sive decline in peripheral blood B-CLL leukemic cells,
which fell from 17,794 cells/μL to 639 cells/μL by week
135 (Figure 2a). This reduction was associated with a pro-
gressive reduction of lymphadenopathy and splenomeg-
aly, and normalization of platelet numbers, leading to a
reduction of his Rai Stage from 4 to 0, an effect observed
in the absence of a continued immune response and with-
out further treatment.
We propose that the selective removal of a putative tumor
precursor cell population has resulted in the delayed dis-
appearance of the more "mature" malignant cells from the
host, as the pipeline of tumor development became inter-
rupted. Our in vivo clinical data offer support to a substan-
tial body of existing pre-clinical analyses of SP cells that
have also suggested that this functional phenotype identi-
fies a precursor cell population for both normal hemat-
opoiesis and other malignancies [3,11-18]. While SP
analysis uses enhanced export of Hoechst dyes to identify
the precursor population, this ABC-transporter mediated
activity [19,20] can also reduce the intracellular concen-
trations, and thus the effectiveness, of many commonly
used chemotherapeutic drugs [11-13]. Hence, tumor SP
cells may therefore both be a tumor precursor population
and have the ability to resist common chemotherapeutic
agents, contributing to disease persistence or relapse. But
although B-CLL SP cells may have greater drug resistance
than non-SP cells, our data show that they may also be
more sensitive to control by immune T cells than the bulk
population. Kipps' group, who first reported that expres-
sion of transgenic murine CD40L on autologous B-CLL
cells could induce an anti-tumor response after intrave-
nous infusion [21], have subsequently shown that vacci-
nated patients develop an antibody response towards
ROR1, a tyrosine kinase receptor involved in recognition
of Wnt5a and involved in cell motility and asymmetric
cell division, characteristics associated with stem cell
behavior [22,23]. While the effects of such immunization
on the malignant SP cells in this study are unknown, we
hypothesize that differential antigen expression by B-CLL
SP cells may allow selective elimination by the immune
system. Here, CD40 activation of autologous B-CLLMolecular Cancer 2009, 8:106 http://www.molecular-cancer.com/content/8/1/106
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tumor cells may upregulate tumor-associated antigens,
such as survivin or RHAMM (receptor for hyaluronic acid-
mediated motility) [24,25] which may be expressed in vivo
by B-CLL SP cells, resulting in their depletion following
immunization.
In summary, we conclude that circulating B-CLL cells con-
tain at least two distinct populations, SP and non-SP, and
that selective removal of the SP component cells can be
followed by the delayed disappearance of non-SP in the
absence of further treatment or a continuing immune
response. These data support the existence of a true tumor
precursor population in this human malignancy and sug-
gest benefit from their removal.
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A distinct CD5+CD19+ SP phenotype is present in B-CLL patient peripheral blood Figure 1
A distinct CD5+CD19+ SP phenotype is present in B-CLL patient peripheral blood. (A) PBMC collected from B-
CLL patient P1300 were stained with Hoechst 33342 dye followed by antibody and propidium iodide labeling and subsequent 
analysis by flow cytometry. Cells were gated on either SP or NSP and examined for expression of CD5 and CD19 showing 
both populations are positive for CD5 and CD19. (B) CD5+CD19+ SP frequency was analyzed longitudinally from PBMC sam-
ples collected prior to CD40L/IL-2 autologous B-CLL vaccination (left panel), during immunization (middle panel) and after 
immunization (right panel), demonstrating the elimination of B-CLL SP cells during treatment.Molecular Cancer 2009, 8:106 http://www.molecular-cancer.com/content/8/1/106
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Figure 2 
B-CLL-specific immunity associated with elimination of B-CLL SP cells and subsequent decrease in leukemic 
cell counts in one patient treated with hCD40L/IL-2. (A) Vaccination with hCD40L/IL-2 gene-modified tumor cells 
resulted in the stable elimination of SP cells in the peripheral blood of one patient (P1300), in whom SP cells did not return 
when immunization was complete. Analysis of leukemic cell number in the peripheral blood of patient P1300 showed a delayed 
decline in circulating B-CLL cells, beginning six months after loss of circulating SP cells. Absolute cell number was calculated 
from the white blood cell (WBC) count multiplied by the percentage of B-CLL (CD5+CD19+), normal B cell (CD5-CD19+) and 
T cells (CD3+), and SP (CD5+CD19+SP+) as determined by flow cytometry. Arrows indicate when patient received vaccination 
(6 vaccine injections total at 0, 1, 2, 6, 8 and 10 weeks). (B) P1300 received 6 subcutaneous injections of hCD40L/IL-2 gene-
modified autologous tumor cells at 0, 1, 2, 6, 8 and 10 weeks (indicated by arrows). B-CLL-specific immunity was measured by 
selecting CD4 and CD8 T cells from PBMC by magnetic separation and measuring IFN-γ and IL-5 by ELIspot following a 36 
hour co-culture with autologous tumor cells (SFC; spot-forming cells per 1 × 105 T cells). ELIspot analysis was performed on 
weeks 0 (pre-vaccine), 3, 12 and 16 (two months after last vaccination).Publish with BioMed Central    and   every 
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